Cargando…

Specific gene expression signatures of low grade meningiomas

INTRODUCTION: Meningiomas are the most common primary central nervous system (CNS) tumors in adults, representing approximately one-third of all primary adult CNS tumors. Although several recent publications have proposed alternative grading systems of meningiomas that incorporate genomic and/or epi...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsitsikov, Erdyni N., Hameed, Sanaa, Tavakol, Sherwin A., Stephens, Tressie M., Tsytsykova, Alla V., Garman, Lori, Bi, Wenya Linda, Dunn, Ian F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10016690/
https://www.ncbi.nlm.nih.gov/pubmed/36937440
http://dx.doi.org/10.3389/fonc.2023.1126550
_version_ 1784907456187465728
author Tsitsikov, Erdyni N.
Hameed, Sanaa
Tavakol, Sherwin A.
Stephens, Tressie M.
Tsytsykova, Alla V.
Garman, Lori
Bi, Wenya Linda
Dunn, Ian F.
author_facet Tsitsikov, Erdyni N.
Hameed, Sanaa
Tavakol, Sherwin A.
Stephens, Tressie M.
Tsytsykova, Alla V.
Garman, Lori
Bi, Wenya Linda
Dunn, Ian F.
author_sort Tsitsikov, Erdyni N.
collection PubMed
description INTRODUCTION: Meningiomas are the most common primary central nervous system (CNS) tumors in adults, representing approximately one-third of all primary adult CNS tumors. Although several recent publications have proposed alternative grading systems of meningiomas that incorporate genomic and/or epigenomic data to better predict meningioma recurrence and progression-free survival, our understanding of driving forces of meningioma development is still limited. OBJECTIVE: To define gene expression signatures of the most common subtypes of meningiomas to better understand cellular processes and signaling pathways specific for each tumor genotype. METHODS: We used RNA sequencing (RNA-seq) to determine whole transcriptome profiles of twenty meningiomas with genomic alterations including NF2 inactivation, loss of chr1p, and missense mutations in TRAF7, AKT1 and KLF4. RESULTS: The analysis revealed that meningiomas with NF2 gene inactivation expressed higher levels of BCL2 and GLI1 compared with tumors harboring TRAF7 missense mutations. Moreover, NF2 meningiomas were subdivided into two distinct groups based on additional loss of chr1p. NF2 tumors with intact chr1p were characterized by the high expression of tumor suppressor PTCH2 compared to NF2 tumors with chr1p loss. Taken together with the high expression of BCL2 and GLI1, these results suggest that activation of Sonic Hedgehog pathway may contribute to NF2 meningioma development. In contrast, NF2 tumors with chr1p loss expressed high levels of transcription factor FOXD3 and its antisense RNA FOXD3-AS1. Examination of TRAF7 tumors demonstrated that TRAF7 regulates a number of biomechanically responsive genes (KRT6a, KRT16, IL1RL1, and AQP3 among others). Interestingly, AKT1 and KLF4 meningiomas expressed genes specific for PI3K/AKT signaling pathway, suggesting overlapping gene signatures between the two subtypes. In addition, KLF4 meningiomas had high expression of carcinoembryonic antigen family members CEACAM6 and CEACAM5. CONCLUSIONS: Each group of meningiomas displayed a unique gene expression signature suggesting signaling pathways potentially implicated in tumorigenesis. These findings will improve our understanding of meningioma tumorigenesis and prognosis.
format Online
Article
Text
id pubmed-10016690
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100166902023-03-16 Specific gene expression signatures of low grade meningiomas Tsitsikov, Erdyni N. Hameed, Sanaa Tavakol, Sherwin A. Stephens, Tressie M. Tsytsykova, Alla V. Garman, Lori Bi, Wenya Linda Dunn, Ian F. Front Oncol Oncology INTRODUCTION: Meningiomas are the most common primary central nervous system (CNS) tumors in adults, representing approximately one-third of all primary adult CNS tumors. Although several recent publications have proposed alternative grading systems of meningiomas that incorporate genomic and/or epigenomic data to better predict meningioma recurrence and progression-free survival, our understanding of driving forces of meningioma development is still limited. OBJECTIVE: To define gene expression signatures of the most common subtypes of meningiomas to better understand cellular processes and signaling pathways specific for each tumor genotype. METHODS: We used RNA sequencing (RNA-seq) to determine whole transcriptome profiles of twenty meningiomas with genomic alterations including NF2 inactivation, loss of chr1p, and missense mutations in TRAF7, AKT1 and KLF4. RESULTS: The analysis revealed that meningiomas with NF2 gene inactivation expressed higher levels of BCL2 and GLI1 compared with tumors harboring TRAF7 missense mutations. Moreover, NF2 meningiomas were subdivided into two distinct groups based on additional loss of chr1p. NF2 tumors with intact chr1p were characterized by the high expression of tumor suppressor PTCH2 compared to NF2 tumors with chr1p loss. Taken together with the high expression of BCL2 and GLI1, these results suggest that activation of Sonic Hedgehog pathway may contribute to NF2 meningioma development. In contrast, NF2 tumors with chr1p loss expressed high levels of transcription factor FOXD3 and its antisense RNA FOXD3-AS1. Examination of TRAF7 tumors demonstrated that TRAF7 regulates a number of biomechanically responsive genes (KRT6a, KRT16, IL1RL1, and AQP3 among others). Interestingly, AKT1 and KLF4 meningiomas expressed genes specific for PI3K/AKT signaling pathway, suggesting overlapping gene signatures between the two subtypes. In addition, KLF4 meningiomas had high expression of carcinoembryonic antigen family members CEACAM6 and CEACAM5. CONCLUSIONS: Each group of meningiomas displayed a unique gene expression signature suggesting signaling pathways potentially implicated in tumorigenesis. These findings will improve our understanding of meningioma tumorigenesis and prognosis. Frontiers Media S.A. 2023-03-01 /pmc/articles/PMC10016690/ /pubmed/36937440 http://dx.doi.org/10.3389/fonc.2023.1126550 Text en Copyright © 2023 Tsitsikov, Hameed, Tavakol, Stephens, Tsytsykova, Garman, Bi and Dunn https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Tsitsikov, Erdyni N.
Hameed, Sanaa
Tavakol, Sherwin A.
Stephens, Tressie M.
Tsytsykova, Alla V.
Garman, Lori
Bi, Wenya Linda
Dunn, Ian F.
Specific gene expression signatures of low grade meningiomas
title Specific gene expression signatures of low grade meningiomas
title_full Specific gene expression signatures of low grade meningiomas
title_fullStr Specific gene expression signatures of low grade meningiomas
title_full_unstemmed Specific gene expression signatures of low grade meningiomas
title_short Specific gene expression signatures of low grade meningiomas
title_sort specific gene expression signatures of low grade meningiomas
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10016690/
https://www.ncbi.nlm.nih.gov/pubmed/36937440
http://dx.doi.org/10.3389/fonc.2023.1126550
work_keys_str_mv AT tsitsikoverdynin specificgeneexpressionsignaturesoflowgrademeningiomas
AT hameedsanaa specificgeneexpressionsignaturesoflowgrademeningiomas
AT tavakolsherwina specificgeneexpressionsignaturesoflowgrademeningiomas
AT stephenstressiem specificgeneexpressionsignaturesoflowgrademeningiomas
AT tsytsykovaallav specificgeneexpressionsignaturesoflowgrademeningiomas
AT garmanlori specificgeneexpressionsignaturesoflowgrademeningiomas
AT biwenyalinda specificgeneexpressionsignaturesoflowgrademeningiomas
AT dunnianf specificgeneexpressionsignaturesoflowgrademeningiomas